Duopharma Biotech Bhd has secured two contracts worth a combined RM116.72 million from the Ministry of Health (MOH) to supply insulin products and injections to government healthcare facilities.
The first contract, valued at RM65.08 million, was awarded to Duopharma Marketing Sdn Bhd and Biocon Sdn Bhd for the supply of recombinant human insulin formulations. Duopharma Marketing will act as the distributor, while Biocon will manufacture and supply the products. This contract runs until May 15, 2026, and requires a RM3.25 million performance bond.
The second contract, worth RM52.54 million, was awarded to Duopharma (M) Sdn Bhd for the supply of insulin injections. It will run until Feb 5, 2028, with a RM1.31 million performance bond required.
Duopharma said the contracts are expected to contribute positively to earnings for the financial year ending Dec 31, 2026. Malaysia has an estimated 4.75 million diabetics, with around 450,000 patients receiving insulin treatment at public healthcare facilities.
Shares of Duopharma closed two sen higher at RM1.48, giving the company a market capitalisation of RM1.42 billion. The stock is up 18.9% year-to-date.
